Study guide
5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence
Key Takeaways Explain This Topic AI
Pre-screening (chart reviews and triage questionnaires) must never involve protocol-specific diagnostic procedures, lab draws, or medication washouts prior to obtaining fully executed, written informed consent.
The Master Screening Log documents all individuals screened, assigning sequential screening numbers and recording specific screen failure reasons while strictly segregating Protected Health Information (PHI).
All inclusion and exclusion criteria must be rigorously verified against verifiable, objective source documentation (certified laboratory reports, pathology, imaging, ECGs) without rounding numbers or clinical assumptions.
Medication washout periods must be calculated based on pharmacokinetics (typically a minimum of 5 half-lives or protocol-defined intervals), with chronic drug discontinuation supervised by a licensed physician.
A qualified physician investigator (PI or Sub-I) must personally conduct the final medical evaluation and sign/date formal eligibility confirmation prior to subject randomization or investigational product administration.
Last updated: August 2026
Screening, Eligibility Verification & Inclusion/Exclusion Adherence
Core Regulatory Standard: The integrity of a clinical trial's scientific conclusions and the safety of human participants depend entirely upon strict, uncompromising adherence to Inclusion and Exclusion (I/E) Criteria . Under ICH GCP E6(R3) Annex 1 section 2.5.2 , the investigator must conduct the trial in compliance with the protocol approved by the IRB/IEC and regulatory authorities. Enrolling a subject who fails to meet even a single inclusion or exclusion criterion constitutes a major protocol violation , compromises subject safety, introduces severe selection bias, and may result in the regulatory invalidation of the subject's data.
1. Pre-Screening vs. Formal Protocol Screening
A clear operational and regulatory boundary exists between pre-screening activities and formal protocol screening . ┌──────────────────────────────────────────────────────────────────────────┐
- │ PRE-SCREENING vs. FORMAL SCREENING │
- ├──────────────────────────────────────────────────────────────────────────┤
- │ PRE-SCREENING (Pre-Consent Phase) │
- │ • Review of existing medical records / EHR charts │
- │ • High-level telephone triage questionnaire (general inquiries) │
- │ • Done under HIPAA Preparatory to Research or Partial Waiver │
- │ • NO protocol-driven blood draws, ECGs, biopsies, or imaging │
- │ • NO discontinuing or altering prescribed medications (washout) │
- ├──────────────────────────────────────────────────────────────────────────┤
- │ FORMAL SCREENING (Post-Consent Phase) │
- │ • Initiated ONLY AFTER fully executed Informed Consent Form (ICF) │
- │ • Assignment of unique Subject Screening Number │
- │ • Execution of protocol-mandated screening evaluations & diagnostic tests│
- │ • Supervised medication washout periods │
- │ • Entry on Master Screening Log │
- └──────────────────────────────────────────────────────────────────────────┘
- The Non-Negotiable Rule of Informed Consent Timing
Under 21 CFR 50.20 and ICH E6(R3) Annex 1 2.8 , no study-specific procedure may be conducted on a human subject until freely given, written informed consent has been obtained.
What is a "Study-Specific Procedure"? Any blood draw, diagnostic scan, physical examination, cognitive test, questionnaire, or medication adjustment performed solely to determine eligibility for the clinical trial.
Existing Clinical Data: If a patient had a routine clinical lab test or MRI performed for standard-of-care purposes prior to consenting, that historical data may be reviewed to assess preliminary eligibility, provided the protocol allows historical laboratory/imaging source data within a defined validity window (e.g., within 28 days prior to Day 1).
2. Screening Logs, Screen Failures & Subject Privacy
The research site must maintain a comprehensive Master Screening Log (also known as the Subject Enrollment and Screening Log) to document the flow of all candidates evaluated for the trial.
A. Purpose of the Screening Log
Trial Feasibility & Recruitment Tracking: Enables the sponsor and CRA to evaluate site screening efficiency, recruitment bottlenecks, and screen failure rates.
GCP Compliance & Audit Trail: Demonstrates that the site systematically screened candidates in accordance with protocol criteria.
Subject Identification: Links the participant's unique trial screening identification number to their medical record number.
B. Segregation of Protected Health Information (PHI)
To comply with HIPAA (45 CFR 164.514) and international privacy frameworks (GDPR), direct identifiers must never appear on sponsor-facing screening logs or electronic Case Report Forms (eCRFs).
Subject Identification Code List (Master Link Log): Kept strictly confidential at the site within the secure Investigator Site File (ISF). It contains the participant's full legal name, date of birth, medical record number (MRN), and assigned Subject Screening Number.
Sponsor-Facing Screening Log: Contains only de-identified data: Subject ID (e.g., SCR-101-004 ), Date of Screening, Gender, Screening Status (Enrolled, Screen Failed, Withdrawn), and the specific Inclusion/Exclusion criterion failed (e.g., "Failed Exclusion Criterion #4: eGFR < 45 mL/min" ). ┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
- │ REPRESENTATIVE SITE SCREENING LOG │
- ├───────────┬──────────────┬──────────────┬───────────────┬───────────────────────────────────────┤
- │ Subject ID│ Screen Date │ Consent Date │ Status │ Primary Reason for Screen Failure │
- ├───────────┼──────────────┼──────────────┼───────────────┼───────────────────────────────────────┤
- │ 101-001 │ 10-JAN-2026 │ 10-JAN-2026 │ Randomize-001 │ N/A (Eligible / Enrolled) │
- │ 101-002 │ 12-JAN-2026 │ 12-JAN-2026 │ Screen Failed │ Exclusion #3: QTc interval = 472 ms │
- │ 101-003 │ 15-JAN-2026 │ 15-JAN-2026 │ Screen Failed │ Inclusion #2: Baseline HbA1c = 6.4% │
- │ 101-004 │ 18-JAN-2026 │ 18-JAN-2026 │ Withdrawn │ Withdrew consent prior to baseline labs│
- │ 101-005 │ 22-JAN-2026 │ 22-JAN-2026 │ Randomize-002 │ N/A (Eligible / Enrolled) │
- └───────────┴──────────────┴──────────────┴───────────────┴───────────────────────────────────────┘
- 3. Rigorous Source Data Verification of Eligibility Criteria
Every single inclusion and exclusion criterion must be verified against objective, verifiable source documentation adhering to ALCOA+ principles.
A. Common Eligibility Verification Traps & Rules
Clinical Criterion Domain Operational Verification Standard Regulatory Trap / Non-Compliant Action
Laboratory Thresholds Must strictly meet numerical cutoffs defined in protocol (e.g., Platelets ≥ 100 × 10 9 / L \ge 100\times 10^9/\text{L} ≥ 100 × 1 0 9 / L ). NO Rounding Numbers: If lab value is 99.6 × 10 9 / L 99.6\times 10^9/\text{L} 99.6 × 1 0 9 / L , the subject has failed. Rounding up to 100 is a major protocol violation.
Electrocardiogram (ECG) QTc interval calculated per protocol formula (Bazett's QTcB or Fridericia's QTcF). Relying on automated machine-printed ECG interpretations without formal over-read by the Investigator/Cardiologist.
Vital Signs & Blood Pressure If protocol requires BP < 140 / 90 mmHg < 140/90\text{ mmHg} < 140/90 mmHg , follow protocol-specified measurement technique (e.g., seated 5 min rest, average of 3 readings). Cherry-picking the single lowest reading out of multiple re-measurements to force eligibility without protocol authorization.
Diagnostic Confirmation Certified histology/pathology reports, molecular biomarker results (e.g., HER2+, EGFR mutation), or imaging scans. Relying solely on patient self-reported medical history or verbal physician summaries without primary source reports in chart.
Reproductive Potential Documented negative serum or highly sensitive urine pregnancy test at screening AND baseline prior to IP dosing. Dispensing IP based on a screening pregnancy test performed 3 weeks prior without a mandatory Day 1 pre-dose confirmatory test.
B. The Strict Prohibition of Eligibility Waivers
In modern clinical trial execution under ICH E6(R3):
EXAM WATCHOUT: Neither the Principal Investigator, the Sponsor, nor the Medical Monitor has the authority to grant an 'eligibility waiver' or 'protocol exception' to enroll a subject who fails to meet protocol-specified inclusion/exclusion criteria.
In the past, sponsors occasionally issued "waivers" allowing borderline patients to enroll. Under current regulatory enforcement, granting such waivers violates the approved protocol, invalidates statistical models, and constitutes an inspection finding on FDA Form 483.
If an eligibility criterion is clinically inappropriate or overly restrictive, the sponsor must submit a formal Protocol Amendment to the regulatory agency and obtain IRB approval before enrolling participants under the revised criteria.
4. Washout Periods & Prohibited Concomitant Medications
Many clinical protocols require a washout period during which prohibited concomitant medications (e.g., biologics, immunosuppressants, strong CYP3A4 inhibitors) must be discontinued before baseline randomization.
A. Pharmacokinetic Principles of Washout Intervals
The duration of a washout period is scientifically determined based on the elimination half-life ( t 1 / 2 t_{1/2} t 1/2 ) of the prohibited drug.
In clinical pharmacology, 5 half-lives ( 5 × t 1 / 2 5 \times t_{1/2} 5 × t 1/2 ) are required to clear >97% of a drug from systemic circulation (and 7 half-lives for >99% clearance).
For biologic agents with prolonged biological activity or receptor occupancy (e.g., monoclonal antibodies), washout periods often extend to 4 to 12 weeks or 5 biological half-lives , whichever is longer. PHARMACOKINETIC ELIMINATION / WASHOUT CURVE
- 100% ┼───●
- │ \
- 50% ┼─────● (1 half-life: 50% remaining)
- │ \
- 25% ┼───────● (2 half-lives: 25% remaining)
- │ \
- 12.5% ┼─────────● (3 half-lives: 12.5% remaining)
- 6.25%┼──────────● (4 half-lives: 6.25% remaining)
- 3.12%┼───────────● (5 half-lives: 3.12% remaining -> STANDARD WASHOUT THRESHOLD)
- 0% └───┴────┴────┴────┴────┴────┴────┴────┴────┴────┴────
- 0 1 2 3 4 5 6 7 (Half-Lives Elapsed)
- B. Ethical and Medical Supervision of Medication Discontinuation
Patient Safety Takes Absolute Precedence: Discontinuing a patient's established medication must never place the patient at significant clinical risk (e.g., abruptly discontinuing anti-epileptic drugs, high-dose corticosteroids, or beta-blockers).
Physician-to-Physician Coordination: The PI must consult with the patient's primary treating physician before tapering or stopping standard-of-care medications.
Screen Failures During Washout: If a patient is washed out of their standard therapy and subsequently fails a baseline screening test (e.g., baseline lab abnormality), the PI must immediately ensure the patient safely resumes their prior prescribed clinical therapy and receives appropriate clinical follow-up.
5. Investigator Medical Confirmation Prior to Randomization
A cornerstone of clinical subject safety is that medical evaluation and final eligibility determination is a non-delegable medical act . ┌──────────────────────────────────────────────────────────────────────────┐
- │ MANDATORY ELIGIBILITY CONFIRMATION WORKFLOW │
- ├──────────────────────────────────────────────────────────────────────────┤
- │ 1. Clinical Research Coordinator compiles complete screening package: │
- │ • Signed/dated ICF copy │
- │ • Certified lab results, ECG tracings, imaging reports │
- │ • Full medical history, physical exam notes, concomitant meds list │
- │ • Completed Inclusion/Exclusion Criteria Checklist │
- ├──────────────────────────────────────────────────────────────────────────┤
- │ 2. Licensed Physician Investigator (PI or Sub-I MD/DO) personally: │
- │ • Reviews all source documents and clinical lab panels │
- │ • Assesses clinical significance of any out-of-range lab values │
- │ • Verifies every single inclusion criterion is MET (Yes) │
- │ • Verifies every single exclusion criterion is ABSENT (No) │
- │ • Signs and dates the formal Investigator Eligibility Attestation │
- ├──────────────────────────────────────────────────────────────────────────┤
- │ 3. Randomization & IP Dispensing Authorization: │
- │ • ONLY AFTER Step 2 is fully executed may the site log into the │
- │ Interactive Response Technology (IRT/IWRS) to randomize subject. │
- └──────────────────────────────────────────────────────────────────────────┘
Exam Watchout: A Clinical Research Coordinator (CRC), study manager, or non-physician investigator who signs an eligibility checklist or randomizes a subject into an interactive response technology (IRT/IWRS) system without prior documented physician review and signature has committed a major GCP non-compliance violation under ICH E6(R3) Principle 1.5 and 4.5.